Cosmos Health Inc (COSM)

Cosmos Health received Nasdaq notices regarding non-compliance but later reported regaining compliance. The company's shares slid in May 2026 as its Q4 2025 earnings miss widened to 660%, posting a loss per share of $0.31. In April 2026, Cosmos Health reported record full-year 2025 revenue of $65.3 million, a 20% increase year-over-year. Cosmos Health announced the completion of Phase 1 execution for Liv18™, with production commencing in April 2026 in the U.S. and projected to generate over $5 million in annual revenue. The company also projected over $2.5 million in incremental annual revenue from Cur18 in the United States and announced the planned U.S. market launch of Cur18b in April 2026. Cosmos Health advanced its AI investments to enhance efficiency, reduce costs, improve customer experience, and drive sales growth. In February 2026, Cosmos Health expanded its Bitcoin holdings to support its long-term digital asset strategy. In November 2025, Cosmos Health reported Q3 2025 adjusted EPS of -$0.17.

Based on historical stock price data, May has shown the highest probability of a positive return for COSM stock at 72.73%, suggesting it could be a favorable month for investment. Conversely, March has the lowest probability of positive returns at 27.27%. The company's stock seasonality going into April also suggests a chance of a "red month," as only 25% of previous Aprils closed higher than March.

Cosmos Health, Inc. is a diversified, vertically integrated global healthcare group operating in the Healthcare sector, specifically in the Medical Distribution and Drug Manufacturers - Specialty & Generic industries. The company's business includes pharmaceutical manufacturing, wholesale distribution, research and development, and digital health activities. Cosmos Health offers a broad portfolio of products, including proprietary pharmaceutical and nutraceutical brands, branded generics, and over-the-counter medications. Through its GMP-certified subsidiary, it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union and has ventured into telehealth services through the acquisition of ZipDoctor, Inc.

Cosmos Health maintains a global geographic footprint, with operations primarily in Europe, specifically Greece and the United Kingdom, where it has manufacturing and distribution facilities. The company has been actively expanding its presence into the United States, Asia, and North America, with offices and distribution centers in Chicago, USA; Thessaloniki and Athens, Greece; and Harlow, UK.

Cosmos Health has actively worked to enhance its brand visibility and reputation, participating in the World Health Expo Dubai 2026 to showcase its expanding portfolio of proprietary nutraceutical and wellness brands. This participation aimed to engage with visitors, partners, and distributors from over 180 countries. While the news of its participation led to a moderate negative market reaction with a 4.77% decline on the day of publication, the event itself was a platform for brand promotion.

Cosmos Health, Inc. has a notable institutional ownership, with 12.61% of its stock owned by institutional investors. Major institutional shareholders include Renaissance Technologies LLC, BlackRock, Inc., Vanguard Group Inc, Geode Capital Management, LLC, Citadel Advisors LLC, XTX Topco Ltd, State Street Corp, and Armistice Capital LLC. Individual investors hold approximately 44.6% of the shares. Andreas Bovopoulos is a significant individual beneficial owner, reporting a stake of 8.152% of the common stock as of April 14, 2026.